argenx SE Sponsored ADR (ARGX)

In the past six months, argenx SE's stock has been influenced by several key events. The company reported strong first-quarter 2026 financial results and FDA approvals for VYVGART and VYVGART Hytrulo, positively influencing the stock. Karen Massey was appointed as the new CEO, with Tim Van Hauwermeiren transitioning to Board Chairperson. Argenx shares fell after the company dropped trials for an eye-disease drug in December 2025. Strong patient uptake of VYVGART has consistently driven revenue growth.

argenx SE has observed a typical effect of seasonality impacting its quarter-over-quarter growth, particularly in the U.S. for its product VYVGART. Despite this, the underlying demand trends for its products remain very strong, indicating a growing and expanding business. The first quarter of 2026 saw some quarter-over-quarter softness due to seasonality, but new patient demand was among the highest ever.

argenx SE is a global immunology company focused on developing antibody-based therapies for severe autoimmune diseases. Its lead product, VYVGART (efgartigimod), is approved for gMG, CIDP, and ITP, available in IV and SC formulations. The company is advancing a pipeline of product candidates, including empasiprubart for MMN and CIDP, and adimanebart, along with other experimental medicines and partnered candidates.

Headquartered in Amsterdam, argenx SE has a significant global presence with operations in the United States, Japan, EMEA, and China. It operates in countries such as Belgium, Switzerland, Germany, France, Canada, the United Kingdom, Italy, Spain, and Australia, with subsidiaries and affiliates established in many of these regions.

In the past year, argenx SE's brand reputation has been shaped by its strong commercial performance and pipeline advancements. The continued growth of VYVGART sales and its expanded approvals have contributed positively to its standing. The company's commitment to improving the lives of patients with severe autoimmune diseases through its Immunology Innovation Program (IIP) also bolsters its reputation. The decision to drop trials for an eye-disease drug in December 2025, which led to a fall in stock price, was a notable event.

argenx SE's ownership structure includes institutional, retail, and individual investors. Major institutional owners include Fmr Llc, Price T Rowe Associates Inc /md/, Janus Henderson Group Plc, Capital World Investors, Artisan Partners Limited Partnership, Avoro Capital Advisors LLC, BlackRock, Inc., Wellington Management Group Llp, Rtw Investments, Lp, Morgan Stanley, T. Rowe Price Group, Inc., The Vanguard Group, Inc., and Baillie Gifford & Co. Institutional investors hold a significant portion of the company's stock.